Pantoprazole-induced Stevens-Johnson Syndrome: A Case-report

Page: [148 - 150] Pages: 3

  • * (Excluding Mailing and Handling)

Abstract

Introduction: Pantoprazole is a proton pump inhibitor mainly used to treat conditions causing excess stomach acid. Stevens-Johnson syndrome (SJS) is a rare bullous disease. The main etiologic factors are drugs, especially antibiotics, anticonvulsants, oxicam and allopurinol. Proton pump inhibitors have been rarely reported as a causative agent in SJS, and only sporadic cases secondary to pantoprazole have just been mentioned in the literature.

Case Report: A 49-year-old woman was referred to the dermatology department for a pruritic generalized eruption, associated with erosive cheilitis. The patient reported self-medication by pantoprazole for two weeks. Physical examination revealed target-like lesions with bullous center in some areas. A skin detachment on the left breast and the neck affecting 10% of the total body surface area was observed. Mucosal examination revealed erosive, painful cheilitis covered by large hemorrhagic crusts and erosions of the nasal cavity. The lesions cleared completely few days after pantoprazole withdrawal and local corticosteroids. Further investigations ruled out infectious etiologies.

Conclusion: This case highlights the possible occurrence of hypersensitivity reactions due to the use of a PPI, which is a widely used medication and a generally well-tolerated drug.

Graphical Abstract

[1]
Ergen EN, Hughey LC. Stevens-johnson syndrome and toxic epidermal necrolysis. JAMA Dermatol 2017; 153(12): 1344.
[http://dx.doi.org/10.1001/jamadermatol.2017.3957] [PMID: 29238841]
[2]
Fracaroli TS, Miranda LQ, Sodré JL, Chaves M, Gripp A. Toxic epidermal necrolysis induced by lansoprazole. An Bras Dermatol 2013; 88(1): 117-20.
[http://dx.doi.org/10.1590/S0365-05962013000100018] [PMID: 23539016]
[3]
Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30(2): 239-45.
[http://dx.doi.org/10.1038/clpt.1981.154] [PMID: 7249508]
[4]
Salloum A, Nasr D, Maalouf D. Dermatologic adverse reactions to proton‐pump inhibitors: A synthetized review. J Cosmet Dermatol 2021; 20(4): 1073-9.
[http://dx.doi.org/10.1111/jocd.13763] [PMID: 33031621]
[5]
Chularojanamontri L, Jiamton S, Manapajon A, et al. Cutaneous reactions to proton pump inhibitors: A case-control study. J Drugs Dermatol 2012; 11(10): e43-7.
[PMID: 23134998]
[6]
Lin C, Wang CW, Hui CYR, et al. Delayed‐type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T‐cell reactivity study. Allergy 2018; 73(1): 221-9.
[http://dx.doi.org/10.1111/all.13235] [PMID: 28658503]
[7]
Kepil Özdemir S, Bavbek S. Hypersensitivity reactions to proton-pump inhibitors: Clinical presentation, diagnosis, and management. Allergy Asthma Proc 2020; 41(2): e37-44.
[http://dx.doi.org/10.2500/aap.2020.41.190033] [PMID: 32122452]
[8]
Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128(1): 35-44.
[http://dx.doi.org/10.1038/sj.jid.5701033] [PMID: 17805350]
[9]
Rodríguez-Martín S, Martín-Merino E, Lerma V, et al. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: A case-population study. Eur J Clin Pharmacol 2019; 75(2): 237-46.
[http://dx.doi.org/10.1007/s00228-018-2569-3] [PMID: 30298362]